Share Price:

APNASPENAspen Pharmacare Hldgs1699381 (0.48%)

Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.

Aspen’s revenue increases 10% underpinned by a strong second half performance

Stephen Saad Aspen Group Chief Executiv

JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.

Aspen building momentum with revenue up 10% to R21,1 billion

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid unaudited interim Group financial results for the six months ended 31 December 2023. SALIENT HIGHLIGHTS Revenue increased by 10% (2% in constant exchange rate (“CER”)) to R21,1 billion (December 2022: R19,2 billion) Normalised EBITDA increased by 2% (-5%… Continue reading Aspen building momentum with revenue up 10% to R21,1 billion

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.